Who Owns Royalty Pharma Stock?
NASDAQ: RPRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 87.67%
- Held by insiders
- 6.49%
- Institutional holders
- 997
- Institutions 87.7%
- Insiders 6.5%
- Public and other 5.8%
Who owns Royalty Pharma stock?
Institutional investors own about 87.7% of Royalty Pharma's shares, spread across 997 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 6.49% of RPRX.
The largest institutional holders are Morgan Stanley (9.64%), Capital International Investors (7.92%) and Blackrock Inc. (6.25%). Together, the top 10 institutions control 43.2% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their RPRX positions and 4 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of RPRX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Morgan Stanley | 42.93M | 9.64% | -1.5% |
| Capital International Investors | 35.27M | 7.92% | +0.8% |
| Blackrock Inc. | 27.83M | 6.25% | +7.4% |
| FMR, LLC | 24.51M | 5.51% | -2.5% |
| State Street Corporation | 12.34M | 2.77% | +12.3% |
| Price (T.Rowe) Associates Inc | 11.19M | 2.51% | +478.7% |
| Swedbank AB | 10.73M | 2.41% | -7.4% |
| BAILLIE GIFFORD & CO | 10.02M | 2.25% | -38.0% |
| Capital World Investors | 9.52M | 2.14% | +18.4% |
| Geode Capital Management, LLC | 8.06M | 1.81% | +2.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of RPRX
| Fund | Shares | % Held |
|---|---|---|
| NEW PERSPECTIVE FUND | 19.65M | 4.41% |
| Growth Fund of America | 7.58M | 1.70% |
| Capital Income Builder | 7.43M | 1.67% |
| MORGAN STANLEY INSTITUTIONAL FUND INC-GROWTH PORTFOLIO | 4.91M | 1.10% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 4.47M | 1.00% |
| TR PRICE-Price (T.Rowe) U.S. Value Equity Trust | 4.23M | 0.95% |
| T. Rowe Price Value Fund, Inc. | 3.12M | 0.70% |
| Advisor Managed Portfolios-Patient Opportunity Trust | 2.50M | 0.56% |
| Victory Portfolios II-VictoryShares Free Cash Flow ETF | 2.44M | 0.55% |
| T. Rowe Price Health Sciences Fund, Inc. | 2.06M | 0.46% |
Frequently asked questions
Who is the largest shareholder of Royalty Pharma?
Morgan Stanley is the largest institutional shareholder of RPRX, owning 9.64% of shares outstanding (42.93M shares) as of its latest 13F filing.
What percentage of Royalty Pharma is owned by institutions?
Institutions own about 87.7% of RPRX shares and 93.8% of the public float.
How much of Royalty Pharma do insiders own?
Insiders, such as officers and directors, own about 6.49% of RPRX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.